3 results
Approved WMOWill not start
Primary:• To compare the overall survival (OS) of patients in the rigosertib group vs the Physician*s Choice group, in all patients and in a subgroup of patients with IPSS-R very high riskSecondary efficacy• To compare rigosertib to Physician*s…
Approved WMOCompleted
To assess uptake of 18F-PD-L1 and 89Zr- nivolumab in tumor lesions.
Approved WMOCompleted
Previous investigations in our lab have provided insight in the requirements for development of such a system and shown the feasibility of the paradigm (Blokland et al., 2011). We have been able to optimize the settings of our proposed system to…